NCT04204122

Vigamox Treatment for Ocular Graft-Versus-Host Disease

Evaluation of Topical Vigamox in the Initial Management of Ocular Graft-Versus-Host Disease

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this study the investigators seek to prospectively measure the response of ocular graft-versus-host disease (GVHD) patients to treatment with topical Vigamox. The investigators will accomplish this by enrolling patients with bilateral ocular GVHD and treating one eye with topical Vigamox and the other eye with a placebo eye drop. By assessing the response to treatment with Vigamox, the investigators hope to identify a role for topical antibiotic treatment in ocular GVHD.

Conditions

• Ocular Graft-versus-host Disease

Interventions

Type	Name	Description
DRUG	Vigamox	-FDA approved medication
DRUG	Placebo	-The placebo is artificial tear drops

Timeline

• Start date: 2020-06-15
• Primary completion: 2025-03-31
• Completion: 2025-03-31
• First posted: 2019-12-18
• Last updated: 2023-08-08

Regulatory

• FDA-regulated drug study